© 1996 American Heart Association, Inc.
Articles |
Autoantibodies Against Oxidized LDL Do Not Predict Atherosclerotic Vascular Disease in Non–Insulin-Dependent Diabetes Mellitus
the Departments of Clinical Nutrition (M.I.J.U., L.N.) and Medicine (L.N., S.Y.-H.), the Kuopio Research Institute of Exercise Medicine (R.R.), and the A.I. Virtanen Institute (J.L., S.Y-H.), University of Kuopio, Kuopio, Finland; the Medical School (P.V.), University of Tampere, Tampere, Finland; and the Division of Vascular Ultrasound Research (M.M.), Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC.
Correspondence to Matti Uusitupa, MD, Department of Clinical Nutrition, University of Kuopio, PO Box 1627, FIN-70211 Kuopio, Finland.
Accelerated atherosclerosis in diabetes has been suggested as being due to an enhanced oxidative modification of LDL. We hypothesized that the titers of autoantibodies against oxidized LDL (oxLDL) may be increased in patients with non–insulin-dependent diabetes mellitus (NIDDM) and that they may contribute to various manifestations of atherosclerosis among such patients. In a 10-year follow-up study of 91 newly diagnosed NIDDM patients and 82 nondiabetic control subjects, autoantibodies against oxLDL (expressed as the ratio of autoantibodies against oxLDL and native LDL) were measured at baseline and after 10 years. Quantitative ultrasonography to examine the intimal-medial thickness of the common carotid artery (a morphological index of arterial wall injury) and carotid bifurcation was performed at the 10-year examination. The relationship of autoantibodies against oxLDL to the occurrence of cardiovascular death, fatal and nonfatal myocardial infarction, stroke, and any cardiovascular event as well as to the intimal-medial thickness of the common carotid artery and carotid bifurcation was evaluated. Associations between these autoantibodies and metabolic variables (fasting glucose, glycosylated hemoglobin, insulin, and serum lipids) in NIDDM patients were also examined. Autoantibodies against oxLDL did not differ between NIDDM and control subjects (NIDDM: baseline, 1.63 and 0.61 to 23.6; 10-year examination, 1.64 and 0.06 to 59.0; control group: baseline, 1.84 and 0.13 to 36.0; 10-year examination, 1.50 and 0.25 to 8.29; median and range, P=.62, baseline; P=.45, 10 year). In both groups, the titers of these autoantibodies measured at baseline and after 10 years significantly correlated with each other (r=.63 for the diabetic and r=.51 for the control group, respectively, P<.001 for each). The frequency of all cardiovascular events was markedly higher in the NIDDM group than in the control group, but autoantibodies against oxLDL had no significant association with any of these events, including cardiovascular mortality. At the 10-year examination the intimal-medial thicknesses of the common carotid artery (1.24±0.36 versus 1.06±0.30 mm, P=.002) and carotid bifurcation (2.11±0.73 versus 1.77±0.82 mm, P=.01) were greater in NIDDM patients than in control subjects, but autoantibodies did not show any association with the intimal-medial thicknesses in either the diabetic or control groups. Autoantibodies against oxLDL indicate the presence of oxidatively modified LDL in vivo, but their titers in the serum do not seem to associate with the excess cardiovascular mortality, morbidity, or intimal-medial thickness of the carotid artery.
Key Words: oxidized LDL • non–insulin-dependent diabetes mellitus • atherosclerosis • cardiovascular mortality • morbidity
This article has been cited by other articles:
 |
|
 |
|
  U. Ravnskov and K. S. McCully Vulnerable Plaque Formation from Obstruction of Vasa Vasorum by Homocysteinylated and Oxidized Lipoprotein Aggregates Complexed with Microbial Remnants and LDL Autoantibodies Ann. Clin. Lab. Sci., January 1, 2009; 39(1): 3 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. McCully Chemical Pathology of Homocysteine. IV. Excitotoxicity, Oxidative Stress, Endothelial Dysfunction, and Inflammation Ann. Clin. Lab. Sci., January 1, 2009; 39(3): 219 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tsimikas, E. S. Brilakis, R. J. Lennon, E. R. Miller, J. L. Witztum, J. P. McConnell, K. S. Kornman, and P. B. Berger Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events J. Lipid Res., February 1, 2007; 48(2): 425 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Dimayuga, X. Zhao, J. Yano, and K.-Y. Chyu Changes in immune responses to oxidized LDL epitopes during aging in hypercholesterolemic apoE(-/-) mice Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1644 - R1650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Piarulli, A. Lapolla, G. Sartore, C. Rossetti, G. Bax, M. Noale, N. Minicuci, C. Fiore, L. Marchioro, E. Manzato, et al. Autoantibodies Against Oxidized LDLs and Atherosclerosis in Type 2 Diabetes Diabetes Care, March 1, 2005; 28(3): 653 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shoenfeld, R. Wu, L. D. Dearing, and E. Matsuura Are Anti-Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective? Circulation, October 26, 2004; 110(17): 2552 - 2558. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stocker and J. F. Keaney Jr. Role of Oxidative Modifications in Atherosclerosis Physiol Rev, October 1, 2004; 84(4): 1381 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Rossi, M. Cesari, R. De Toni, M. Zanchetta, G. Maiolino, L. Pedon, C. Ganzaroli, P. Maiolino, and A. C. Pessina Antibodies to Oxidized Low-Density Lipoproteins and Angiographically Assessed Coronary Artery Disease in White Patients Circulation, November 18, 2003; 108(20): 2467 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Virella and M. F. Lopes-Virella Lipoprotein Autoantibodies: Measurement and Significance Clin. Vaccine Immunol., July 1, 2003; 10(4): 499 - 505. [Full Text] [PDF]
|
|
|
|
 |
|
 A. MERTENS and P. HOLVOET Oxidized LDL and HDL: antagonists in atherothrombosis FASEB J, October 1, 2001; 15(12): 2073 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Inoue, T. Uchida, H. Kamishirado, K. Takayanagi, T. Hayashi, and S. Morooka Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease J. Am. Coll. Cardiol., March 1, 2001; 37(3): 775 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hulthe, O. Wiklund, E. Hurt-Camejo, and G. Bondjers Antibodies to Oxidized LDL in Relation to Carotid Atherosclerosis, Cell Adhesion Molecules, and Phospholipase A2 Arterioscler Thromb Vasc Biol, February 1, 2001; 21(2): 269 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hulthe, L. Bokemark, and B. Fagerberg Antibodies to Oxidized LDL in Relation to Intima-Media Thickness in Carotid and Femoral Arteries in 58-Year-Old Subjectively Clinically Healthy Men Arterioscler Thromb Vasc Biol, January 1, 2001; 21(1): 101 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Niskanen, M. K. Karvonen, R. Valve, M. Koulu, U. Pesonen, M. Mercuri, R. Rauramaa, J. Töyry, M. Laakso, and M. I. J. Uusitupa Leucine 7 to Proline 7 Polymorphism in the Neuropeptide Y Gene Is Associated with Enhanced Carotid Atherosclerosis in Elderly Patients with Type 2 Diabetes and Control Subjects J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2266 - 2269. [Abstract] [Full Text]
|
|
|
|
|
|
M. Fukumoto, T. Shoji, M. Emoto, T. Kawagishi, Y. Okuno, and Y. Nishizawa Antibodies Against Oxidized LDL and Carotid Artery Intima-Media Thickness in a Healthy Population Arterioscler Thromb Vasc Biol, March 1, 2000; 20(3): 703 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Erkkila, O. Narvanen, S. Lehto, M. I. J. Uusitupa, and S. Yla-Herttuala Autoantibodies Against Oxidized Low-Density Lipoprotein and Cardiolipin in Patients With Coronary Heart Disease Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 204 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ahmed, J. Trifunovic, B. Stegmayr, G. Hallmans, and A. K. Lefvert Autoantibodies Against Oxidatively Modified LDL Do Not Constitute a Risk Factor for Stroke : A Nested Case-Control Study Stroke, December 1, 1999; 30(12): 2541 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Lehtimaki, S. Lehtinen, T. Solakivi, M. Nikkila, O. Jaakkola, H. Jokela, S. Yla-Herttuala, J. S. Luoma, T. Koivula, and T. Nikkari Autoantibodies Against Oxidized Low Density Lipoprotein in Patients With Angiographically Verified Coronary Artery Disease Arterioscler Thromb Vasc Biol, January 1, 1999; 19(1): 23 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Koskinen, C. Enockson, M. F. Lopes-Virella, and G. Virella Preparation of a Human Standard for Determination of the Levels of Antibodies to Oxidatively Modified Low-Density Lipoproteins Clin. Vaccine Immunol., November 1, 1998; 5(6): 817 - 822. [Abstract] [Full Text]
|
|
|
|
|
|
J. Hulthe, J. Wikstrand, A. Lidell, I. Wendelhag, G. K. Hansson, and O. Wiklund Antibody Titers Against Oxidized LDL Are Not Elevated in Patients With Familial Hypercholesterolemia Arterioscler Thromb Vasc Biol, August 1, 1998; 18(8): 1203 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Jialal Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein Clin. Chem., August 1, 1998; 44(8): 1827 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Reaven, S. Merat, F. Casanada, M. Sutphin, and W. Palinski Effect of Streptozotocin-Induced Hyperglycemia on Lipid Profiles, Formation of Advanced Glycation Endproducts in Lesions, and Extent of Atherosclerosis in LDL Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, October 1, 1997; 17(10): 2250 - 2256. [Abstract] [Full Text]
|
|